Home › Companies › DYNE THERAPEUTICS INC. › 2023-2024
At DYNE THERAPEUTICS INC.'s shareholder meeting held May 22, 2024, in the 2023-2024 proxy season, 54 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 735 separate fund positions. On the most widely held item on that ballot — The election of three Class I directors, each to serve for a three-year term expiring at the… — FOR was 87% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: DYNE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 24, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and DYNE THERAPEUTICS INC.’s Form 8-K, filed May 24, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 22, 2024: 4 items on DYNE THERAPEUTICS INC.’s Form 8-K, filed May 24, 2024: 1 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore DYNE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are DYNE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Carlo Incerti, M.D. | 61,028,245 | -- | -- | 8,752,856 | 5,235,919 | 87% | Not verified | — |
| Elect Director: Catherine Stehman-Breen, M.D. | 55,026,485 | -- | -- | 14,325,362 | 5,665,173 | 79% | Not verified | — |
| Elect Director: John G. Cox | 69,763,860 | -- | -- | 32,767 | 5,220,393 | 99.9% | Not verified | — |
| B) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 74,962,217 | 12,377 | 42,426 | -- | -- | 99.9% | Approved | — |
Source: DYNE THERAPEUTICS INC., Form 8-K, filed with the SEC on May 24, 2024 — read the filing on EDGAR.
Each item below shows how the 54 asset managers that disclosed a DYNE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Carlo Incerti, M.D.
DYNE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Carlo Incerti, M.D.”): 61,028,245 for, 8,752,856 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 16,266,501 for, 3,205,547 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,215,856 | 0 | 0 | 2,378,403 | Mixed |
| Vanguard | 3,336,892 | 0 | 0 | 0 | For |
| State Street | 2,917,957 | 0 | 0 | 3,993 | For |
| BlackRock | 2,862,125 | 0 | 0 | 0 | For |
| Federated Hermes | 1,100,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 996,149 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 963,634 | 0 | 0 | 0 | For |
| Prudential/PGIM | 662,251 | 0 | 0 | 0 | For |
| TIAA | 513,498 | 0 | 0 | 0 | For |
| Charles Schwab | 461,522 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 446,854 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 241,708 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 216,750 | Withhold |
| JANUS INVESTMENT FUND | 202,314 | 0 | 0 | 0 | For |
| Equitable | 106,300 | 0 | 0 | 57,760 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 103,627 | 0 | 0 | 0 | For |
| SEI | 79,267 | 0 | 0 | 0 | For |
| Lincoln Financial | 47,900 | 0 | 0 | 24,976 | Mixed |
| Russell Investments | 69,781 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 67,076 | Withhold |
| Northern Trust | 0 | 0 | 0 | 41,770 | Withhold |
| New York Life | 11,183 | 0 | 0 | 27,672 | Mixed |
| John Hancock | 17,000 | 0 | 0 | 20,774 | Mixed |
| Pacific Life | 30,609 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 29,138 | Withhold |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Catherine Stehman-Breen, M.D.
DYNE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Catherine Stehman-Breen, M.D.”): 55,026,485 for, 14,325,362 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 12,811,076 for, 6,660,972 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,594,259 | 0 | 0 | 0 | For |
| Vanguard | 3,336,892 | 0 | 0 | 0 | For |
| State Street | 2,923 | 0 | 0 | 2,919,027 | Withhold |
| BlackRock | 2,862,125 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 0 | 0 | 1,100,000 | Withhold |
| T. Rowe Price | 996,149 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 963,634 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 0 | 0 | 662,251 | Withhold |
| TIAA | 0 | 0 | 0 | 513,498 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 461,522 | Withhold |
| WASATCH FUNDS TRUST | 446,854 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 241,708 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 216,750 | Withhold |
| JANUS INVESTMENT FUND | 202,314 | 0 | 0 | 0 | For |
| Equitable | 106,300 | 0 | 0 | 57,760 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 103,627 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 79,267 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 72,876 | Withhold |
| Russell Investments | 0 | 0 | 0 | 69,781 | Withhold |
| ProShares | 0 | 0 | 0 | 67,076 | Withhold |
| Northern Trust | 41,770 | 0 | 0 | 0 | For |
| New York Life | 11,183 | 0 | 0 | 27,672 | Mixed |
| John Hancock | 17,000 | 0 | 0 | 20,774 | Mixed |
| Pacific Life | 30,609 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 29,138 | Withhold |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: John G. Cox
DYNE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John G. Cox”): 69,763,860 for, 32,767 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 19,452,048 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,594,259 | 0 | 0 | 0 | For |
| Vanguard | 3,336,892 | 0 | 0 | 0 | For |
| State Street | 2,921,950 | 0 | 0 | 0 | For |
| BlackRock | 2,862,125 | 0 | 0 | 0 | For |
| Federated Hermes | 1,100,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 996,149 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 963,634 | 0 | 0 | 0 | For |
| Prudential/PGIM | 662,251 | 0 | 0 | 0 | For |
| TIAA | 513,498 | 0 | 0 | 0 | For |
| Charles Schwab | 461,522 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 446,854 | 0 | 0 | 0 | For |
| Dimensional | 241,708 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 216,750 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 202,314 | 0 | 0 | 0 | For |
| Equitable | 164,060 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 103,627 | 0 | 0 | 0 | For |
| SEI | 79,267 | 0 | 0 | 0 | For |
| Lincoln Financial | 72,876 | 0 | 0 | 0 | For |
| Russell Investments | 69,781 | 0 | 0 | 0 | For |
| ProShares | 67,076 | 0 | 0 | 0 | For |
| Northern Trust | 41,770 | 0 | 0 | 0 | For |
| New York Life | 38,855 | 0 | 0 | 0 | For |
| John Hancock | 37,774 | 0 | 0 | 0 | For |
| Pacific Life | 30,609 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,138 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: THE RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
DYNE THERAPEUTICS INC.’s own tally for this item (“b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 74,962,217 for, 12,377 against — passed, per its Form 8-K filed May 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 19,472,048 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,594,259 | 0 | 0 | 0 | For |
| Vanguard | 3,336,892 | 0 | 0 | 0 | For |
| State Street | 2,921,950 | 0 | 0 | 0 | For |
| BlackRock | 2,862,125 | 0 | 0 | 0 | For |
| Federated Hermes | 1,100,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 996,149 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 963,634 | 0 | 0 | 0 | For |
| Prudential/PGIM | 662,251 | 0 | 0 | 0 | For |
| TIAA | 513,498 | 0 | 0 | 0 | For |
| Charles Schwab | 461,522 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 446,854 | 0 | 0 | 0 | For |
| Dimensional | 241,708 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 216,750 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 202,314 | 0 | 0 | 0 | For |
| Equitable | 164,060 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 103,627 | 0 | 0 | 0 | For |
| SEI | 79,267 | 0 | 0 | 0 | For |
| Lincoln Financial | 72,876 | 0 | 0 | 0 | For |
| Russell Investments | 69,781 | 0 | 0 | 0 | For |
| ProShares | 67,076 | 0 | 0 | 0 | For |
| Northern Trust | 41,770 | 0 | 0 | 0 | For |
| New York Life | 38,855 | 0 | 0 | 0 | For |
| John Hancock | 37,774 | 0 | 0 | 0 | For |
| Pacific Life | 30,609 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,138 | 0 | 0 | 0 | For |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,382,638 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 4.11% |
| 2 | Vanguard | 3.82% |
| 3 | State Street | 3.34% |
| 4 | BlackRock | 3.28% |
| 5 | Federated Hermes | 1.26% |
| 6 | T. Rowe Price | 1.14% |
| 7 | FRANKLIN STRATEGIC SERIES | 1.10% |
| 8 | Prudential/PGIM | 0.76% |
| 9 | TIAA | 0.59% |
| 10 | Charles Schwab | 0.53% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| JANUS HENDERSON GROUP PLC | 11.85% | 13G |
| Vanguard Group | 11.17% | 13F |
| RA Capital Management, L.P. | 11.12% | 13G |
| BlackRock | 11.03% | 13F |
| Jason Rhodes | 9.25% | DEF14A |
| Entities affiliated with Atlas Venture Fund XI, L.P. | 9.18% | DEF14A |
| Dirk Kersten | 9.05% | DEF14A |
| Forbion Capital Fund IV Cooperatief U.A. | 8.98% | DEF14A |
| Atlas Venture Fund XI, L.P. | 6.52% | 13G |
| FMR (Fidelity) | 6.18% | 13F |
Percentages above are of 87,382,638 shares outstanding, as reported by DYNE THERAPEUTICS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DYNE THERAPEUTICS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
DYNE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “DYNE THERAPEUTICS (DYN) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/dyne-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.